<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Benefits and risks of adding oxaliplatin to adjuvant chemotherapy in patients with high-risk stage II colon cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Benefits and risks of adding oxaliplatin to adjuvant chemotherapy in patients with high-risk stage II colon cancer</h1>
<div class="graphic"><div class="figure"><div class="ttl">Benefits and risks of adding oxaliplatin to adjuvant chemotherapy in patients with high-risk stage II colon cancer</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup span="2" width="10%"></colgroup><colgroup span="2" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Outcome</td> <td class="subtitle1" rowspan="2">Results</td> <td class="subtitle1" colspan="2">Absolute effect estimates</td> <td class="subtitle1" rowspan="2">Quality of evidence</td> <td class="subtitle1" rowspan="2">Plain language summary</td> </tr> <tr> <td class="subtitle2">FU + LV</td> <td class="subtitle2">FOLFOX</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Grade 3 peripheral sensory neuropathy</td> <td class="divider_bottom" rowspan="2">RR: 69.0 (95% CI, 17.0 to 278.0)<br/> (2219 patients in one study during treatment)</td> <td>2 per 1000</td> <td>138 per 1000</td> <td class="divider_bottom" rowspan="2">Moderate*</td> <td class="divider_bottom" rowspan="2">FOLFOX worsens grade 3 peripheral sensory neuropathy during treatment</td> </tr> <tr class="divider_bottom"> <td colspan="2">Difference: 136 more per 1000 (95% CI, 32 more to 554 more)</td> </tr> <tr> <td class="divider_bottom" rowspan="2">OS</td> <td class="divider_bottom" rowspan="2">HR: 0.91 (95% CI, 0.61 to 1.36)<br/> (569 patients in one study)<br/> Follow-up median: 80 months</td> <td>167 per 1000</td> <td>153 per 1000</td> <td class="divider_bottom" rowspan="2">Low<sup>¶</sup></td> <td class="divider_bottom" rowspan="2">FOLFOX may have little or no effect on OS in patients at high risk of recurrence</td> </tr> <tr class="divider_bottom"> <td colspan="2">Difference: 14 fewer per 1000 (95% CI, 62 fewer to 53 more)</td> </tr> <tr> <td class="divider_bottom" rowspan="2">DFS</td> <td class="divider_bottom" rowspan="2">HR: 0.72 (95% CI, 0.51 to 1.01)<br/> (569 patients in one study)<br/> Follow-up median: 63 months</td> <td>254 per 1000</td> <td>190 per 1000</td> <td class="divider_bottom" rowspan="2">Low<sup>¶</sup></td> <td class="divider_bottom" rowspan="2">FOLFOX may have little or no effect on DFS in patients at high risk of recurrence</td> </tr> <tr class="divider_bottom"> <td colspan="2">Difference: 64 fewer per 1000 (95% CI, 115 fewer to 2 more)</td> </tr> <tr> <td rowspan="2">TTR</td> <td rowspan="2">HR: 0.62 (95% CI, 0.41 to 0.92)<br/> (569 patients in one study)<br/> Follow-up median: 63 months</td> <td>212 per 1000</td> <td>137 per 1000</td> <td rowspan="2">Low<sup>¶</sup></td> <td rowspan="2">FOLFOX may improve TTR in patients at high risk of recurrence</td> </tr> <tr> <td colspan="2">Difference: 75 fewer per 1000 (95% CI, 119 fewer to 13 fewer)</td> </tr> </tbody></table></div><div class="graphic_footnotes">FU: fluorouracil; 
	LV: leucovorin calcium; 
	FOLFOX: fluorouracil, leucovorin, and oxaliplatin; 
	RR: relative risk; 
	OS: overall survival; 
	HR: hazard ratio; 
	DFS: disease-free survival; 
	TTR: time to recurrence; 
	PSN: peripheral sensory neuropathy.<br/>
	
	* Downgrade for wide CI. Grade 3 PSN during treatment was reported in 138 patients (12.5%) in the FOLFOX4 group and 0.2% of the patients in the LV 1 FU group. At 18 and 48 months, 0.7% of FOLFOX-treated patients experienced Grade 3 PSN.<br/>
	
	¶ Indirectness: population includes stage III patients (MOSAIC trial, 2009). MOSAIC analyses conducted in high-risk subpopulation are considered exploratory.</div><div class="graphic_reference">From: Baxter NN, Kennedy EB, Bergsland E, et al. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. J Clin Oncol 2021. DOI: <a href="https://ascopubs.org/doi/pdf/10.1200/JCO.21.02538" target="_blank">10.1200/JCO.21.02538</a>. Copyright © 2021 American Society of Clinical Oncology. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.</div><div id="graphicVersion">Graphic 134891 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
